Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image: Generic semaglutide injection pens and diabetes-care materials illustrate Apotex’s Health Canada approval for Apo-Semaglutide Injection, a generic Ozempic equivalent that could reshape GLP-1 access and diabetes treatment affordability in Canada.
Pharma & Biotech

Why Apotex’s Apo-Semaglutide approval could reshape Canada’s diabetes drug market

Canada has generic Ozempic momentum. Apotex’s approval turns GLP-1 access into a pricing and supply-chain test.

Read More
Representative image of a pediatric growth assessment in a clinical setting. BioMarin’s latest VOXZOGO data highlight how long-term achondroplasia treatment is moving beyond height gains toward arm span, bone health, and broader skeletal development outcomes.
Pharma & Biotech

Why BioMarin’s VOXZOGO update matters ahead of hypochondroplasia Phase 3 data

VOXZOGO is no longer just a height story. BioMarin now needs long-term data to support a broader skeletal dysplasia strategy.

Read More
Representative image: Ophthalmology researchers evaluate retinal imaging data as Spinogenix’s tazbentetol preclinical results raise new questions about synaptic regeneration, glaucoma neuroprotection, and diabetic retinopathy treatment strategies.
Pharma & Biotech

Why Spinogenix’s tazbentetol data could reshape glaucoma and diabetic retinopathy research

Retinal disease care still targets drivers. Spinogenix is testing whether synaptic regeneration can protect vision when damage continues.

Read More
Representative image: Arrowhead Pharmaceuticals’ REDEMPLO approval in Australia highlights the growing role of RNAi therapies in treating familial chylomicronemia syndrome and severe triglyceride disorders.
Pharma & Biotech

Arrowhead just unlocked Australia for REDEMPLO, but the bigger RNAi test starts now

Arrowhead has regulatory momentum in rare lipid disease. The harder test is turning REDEMPLO approval into durable global uptake.

Read More
Representative image: AstraZeneca’s TRUQAP prostate cancer push highlights the growing role of targeted therapy and PTEN testing in metastatic hormone-sensitive prostate cancer treatment.
Pharma & Biotech

Why AstraZeneca’s TRUQAP ODAC vote could reshape PTEN-deficient prostate cancer treatment

TRUQAP has ODAC support, but toxicity and survival maturity still matter. AstraZeneca’s prostate cancer expansion now faces FDA’s final test.

Read More
Representative image: Corcept Therapeutics’ dazucorilant survival signal in amyotrophic lateral sclerosis highlights how ALS clinical trials are shifting attention from short-term functional scores to longer-term survival outcomes.
Pharma & Biotech

A failed ALS trial still showed a stunning survival signal. Can Corcept turn it into Phase 3 proof?

A failed ALS endpoint meets a striking survival signal. Corcept now faces the harder test: proving dazucorilant in Phase 3.

Read More
Representative image: A child undergoing an eye examination in a modern ophthalmology clinic, reflecting Sydnexis’ Phase 3 SYD-101 data focus on low-dose atropine treatment for fast-progressing pediatric myopia.
Pharma & Biotech

Can Sydnexis’ SYD-101 data sharpen the case for low-dose atropine in fast-progressing pediatric myopia?

Pediatric myopia is rising fast, but U.S. drug options remain thin. Sydnexis’ SYD-101 data may sharpen the regulatory race.

Read More
Representative image: A hematology clinician reviews treatment data in a clinical lab setting as Incyte’s FDA approval of once-daily Jakafi XR highlights the next phase of ruxolitinib therapy for myelofibrosis, polycythemia vera and graft-versus-host disease.
Pharma & Biotech

Can Jakafi XR defend Incyte’s ruxolitinib franchise as dosing convenience becomes strategic?

Jakafi is mature, but dosing still matters. Incyte’s Jakafi XR approval could extend ruxolitinib’s strategic life in hematology.

Read More
Representative image: Continuous glucose monitoring data in a clinical setting highlights the regulatory and clinical questions surrounding Rezolute’s ersodetug data for congenital hyperinsulinism after the Phase 3 sunRIZE study.
Pharma & Biotech

Rezolute’s ersodetug data deepens the congenital hyperinsulinism regulatory debate

Rezolute, Inc. has presented expanded Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism at the Pediatric Endocrine Society Annual Meeting, adding continuous glucose monitoring outcomes and open-label extension observations to a program that previously missed its primary endpoint. The update places the late-stage rare disease biotech firm in a complex regulatory position, as the

Read More
Representative image: A clinical consultation on advanced breast cancer treatment, reflecting how VEPPANU’s FDA approval could bring targeted protein degradation and oral endocrine therapy into sharper focus for ESR1-mutated breast cancer care.
Pharma & Biotech

How Arvinas and Pfizer’s VEPPANU approval tests the commercial future of PROTAC drugs

Arvinas Inc., with partner Pfizer Inc., has received U.S. Food and Drug Administration approval for VEPPANU, also known as vepdegestrant, for adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer after disease progression following at least one line of endocrine therapy. The approval gives the oncology market its

Read More